Akesobio
HKEX: 9926 ~$3B MCAP
Akesobio is a Chinese clinical-stage biopharmaceutical company developing innovative antibodies for oncology and inflammatory diseases, including the PD-1xVEGF bispecific ivonescimab partnered with Summit Therapeutics.
Company Info
Sector:Biopharmaceuticals / Antibody therapeutics
Headquarters:Zhongshan, Guangdong, China
Founded:2012
Website:www.akesobio.com/
Recent News
No recent news updates available for this company.